查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
BPH 治療市場：2019-2029 年全球市場規模、佔有率、趨勢分析、機遇和預測報告
市場調查報告書
商品編碼
1310371

BPH 治療市場：2019-2029 年全球市場規模、佔有率、趨勢分析、機遇和預測報告

Benign Prostatic Hyperplasia Treatment Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Therapy ; By Therapeutic Class ; By Region
出版日期: | 出版商: Blueweave Consulting | 英文 400 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計到2029年全球良性前列腺增生（BPH）治療市場將達到74億美元

全球良性前列腺增生（BPH）治療市場受到全球BPH患病率不斷上升、易患BPH的老年人口不斷增加以及微創治療方案進步的推動，因此正在蓬勃發展。

領先的戰略諮詢和市場研究公司 BlueWeave Consulting 最近的一項研究估計，2022 年全球良性前列腺增生 (BPH) 治療市場價值將達到 59.7797 億美元。 BlueWeave預測，在2023-2029年的預測期內，全球前列腺增生症治療市場規模將以3.13%的複合年複合成長率穩定成長，到2029年達到73.8199億美元。全球良性前列腺增生（BPH）治療市場的主要成長促進因素包括提高公眾對可用治療方案的認知。諸如經尿道前列腺電切術（TURP）的引入等技術進步也在推動市場成長方面發揮著關鍵作用。 TURP 是一種內視鏡電外科手術，可切除部分前列腺以緩解生長引起的阻塞。個人醫療保健支出能力的提高和醫療保健基礎設施的顯著改善，尤其是在新興國家，預計將進一步推動市場的擴張。良性前列腺增生及其相關泌尿系統疾病患病率的增加是市場成長的重要促進因素。炎症反應增加、交感神經活動和氧化應激等因素會導致 BPH 的發生，尤其是在肥胖患者中。體內荷爾蒙的變化也與BPH以及BPH的發展有關，擴大了BPH藥物的市場。此外，由於醫療保健基礎設施的改善、未滿足的醫療保健需求的增加以及研發 (R&D) 力度的加大，尚未開發的新興經濟體提供了巨大的市場發展機會。因此，這些方面預計將在分析期間推動全球良性前列腺增生症市場的擴張。然而，與 BPH 治療程序相關的高成本以及與某些治療方案相關的副作用和併發症預計將在預測期內抑制整個市場的成長。

該報告的詳細分析提供了有關全球良性前列腺增生治療市場的成長潛力、未來趨勢和統計數據的資訊。它還揭示了推動整體市場規模預測的因素。該報告致力於為決策者提供全球良性前列腺增生治療市場的最新技術趨勢以及行業見解，以做出明智的戰略決策。它還分析了市場的成長促進因素、挑戰和競爭力。

目錄

第1章 研究框架

第2章 執行摘要

第3章 全球良性前列腺增生（BPH）治療市場洞察

  • 行業價值鏈分析
  • DROC分析
    • 成長動力
      • 全球良性前列腺增生症患病率增加
      • 人口老齡化增加易患良性前列腺增生
      • 微創治療方案的進展
    • 抑制因素
      • 治療 BPH 的費用較高
      • 與特定治療方案相關的副作用和併發症
    • 機會
      • 開發新的、更有效的治療方案。
      • 加大研發投入。
    • 任務
      • 市場相關人員之間的激烈競爭
      • 部分地區先進治理技術引進滯後
  • 技術進步/最新發展
  • 監管框架
  • 波特五力分析

第4章 全球良性前列腺增生（BPH）治療市場概述

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 通過治療
      • 單一療法
      • 伴隨藥物治療
    • 按治療類別
      • α阻滯劑
      • 5-α-還原酶抑製劑
      • 磷酸二酯酶5抑製劑
      • 其他
    • 按地區
      • 北美
      • 歐洲
      • 亞太地區 (APAC)
      • 拉丁美洲 (LATAM)
      • 中東和非洲 (MEA)

第5章 北美良性前列腺增生（BPH）治療市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 通過治療
    • 按治療類別
    • 按國家/地區
      • 美國
      • 加拿大

第6章 歐洲良性前列腺增生（BPH）治療市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 通過治療
    • 按治療類別
    • 按國家/地區
      • 德國
      • 英國
      • 義大利
      • 法國
      • 西班牙
      • 比利時
      • 俄羅斯
      • 荷蘭
      • 其他歐洲國家

第7章 亞太良性前列腺增生（BPH）治療市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 通過治療
    • 按治療類別
    • 按國家/地區
      • 中國
      • 印度
      • 日本
      • 韓國
      • 澳大利亞和紐西蘭
      • 印度尼西亞
      • 馬來西亞
      • 新加坡
      • 越南
      • 亞太地區其他國家

第8章 拉丁美洲良性前列腺增生（BPH）治療市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 通過治療
    • 按治療類別
    • 按國家/地區
      • 巴西
      • 墨西哥
      • 阿根廷
      • 秘魯
      • 拉丁美洲其他地區

第9章 中東和非洲良性前列腺增生（BPH）治療市場

  • 2019-2029年市場規模及預測
    • 按金額
  • 市場佔有率及預測
    • 通過治療
    • 按治療類別
    • 按國家/地區
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 科威特
      • 南非
      • 奈及利亞
      • 阿爾及利亞
      • MEA 的其餘部分

第10章 競爭格局

  • 主要公司及其產品列表
  • 2022 年全球良性前列腺增生 (BPH) 治療市場佔有率分析
  • 通過管理參數進行競爭基準測試
  • 主要戰略發展（合併、收購、合作夥伴關係等）

第11章COVID-19 感染對全球 BPH（BPH）治療市場的影響

第12章公司簡介（公司簡介、財務矩陣、競爭格局、關鍵人才、主要競爭、聯繫地址、戰略展望、SWOT分析）

  • Astellas Pharma Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • AstraZeneca plc
  • Johnson & Johnson
  • Pfizer Inc.
  • Abbott Laboratories
  • Boston Scientific Corporation
  • Medtronic plc
  • Urologix, LLC
  • Teleflex Incorporated
  • Olympus Corporation
  • Merck & Co., Inc.
  • Allergan plc
  • Endo International plc
  • Other Prominent Players

第13章關鍵戰略建議

第14章調查方法

簡介目錄
Product Code: BWC22256

Global Benign Prostatic Hyperplasia (BPH) Treatment Market Size Set to Touch USD 7.4 Billion by 2029.

Global benign prostatic hyperplasia (BPH) treatment market is flourishing, because of increasing prevalence of BPH across the world, growing geriatric population prone to BPH, and advancements in minimally invasive treatment options.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated global benign prostatic hyperplasia (BPH) treatment market size at USD 5,977.97 million in 2022. During the forecast period between 2023 and 2029, BlueWeave expects global benign prostatic hyperplasia (BPH) treatment market size to grow at a steady CAGR of 3.13% reaching a value of USD 7,381.99 million by 2029. Major growth drivers for the global benign prostatic hyperplasia (BPH) treatment market include an increasing awareness among the public regarding available treatment options. Technological advancements, such as the introduction of transurethral resection of the prostate (TURP), have also played a significant role in driving market growth. TURP is an endoscopic electrosurgical procedure that involves the removal of a portion of the prostate gland to alleviate blockage caused by abnormal growth. The expanding individual healthcare expenditure capacities and notable improvements in healthcare infrastructure, particularly in developing countries, are expected to further propel the market's expansion. The growing prevalence of benign prostatic hyperplasia and the associated urological conditions are significant drivers of market growth. Factors such as elevated inflammatory response, sympathetic nerve activity, and oxidative stress contribute to the development of BPH, particularly in obese patients. Hormonal changes in the body are also linked to prostate enlargement and the development of BPH, thereby expanding the market for BPH medications. Also, untapped emerging economies present significant opportunities for market development due to improved healthcare infrastructure, a growing demand for unmet healthcare needs, and increased efforts in research and development (R&D). Hence, such aspects are expected to boost the expansion of global BPH market during the period in analysis. However, high costs associated with BPH treatment procedures and adverse effects and complications associated with certain treatment options are anticipated to restrain the growth of overall market during the forecast period.

Global Benign Prostatic Hyperplasia (BPH) Treatment Market - Overview:

Benign prostatic hyperplasia (BPH), commonly referred to as the enlargement of the prostate gland, tends to become more prevalent in aging men. An enlarged prostate gland can lead to urinary symptoms, such as urinary retention, and may also affect the bladder, urethra, or kidneys. Treatment options for BPH encompass a range of approaches, including prescription medications, active surveillance, monotherapy and combination therapy, phytotherapy, as well as minimally invasive and invasive surgeries. These procedures often involve the utilization of resectoscopes, urology lasers, radiofrequency ablation devices, prostatic stents, and implants. Active surveillance serves as one of the primary treatment methods for BPH. This approach entails closely monitoring the condition without active intervention. Under the guidance of a urologist, regular monitoring of the BPH will take place, typically through annual physical examinations. The focus will be on identifying any new or worsening symptoms before considering further interventions. Additionally, lifestyle modifications, including dietary adjustments and exercise, are commonly recommended to prevent or manage symptoms. Active surveillance is typically suitable for men experiencing mild to moderate symptoms or those who are not significantly bothered by BPH symptoms. However, if symptoms worsen or new ones emerge, the healthcare provider may recommend transitioning to active therapy.

Impact of COVID-19 on Global Benign Prostatic Hyperplasia (BPH) Treatment Market:

COVID-19 pandemic adversely affected global benign prostatic hyperplasia (BPH) treatment market. The healthcare system's focus on managing and containing the virus has resulted in a redirection of resources, affecting the diagnosis and treatment of non-emergency conditions, such as BPH. Delayed elective surgeries, reduced outpatient visits, and disruptions in the supply chain of medications and medical devices have impacted the market. Moreover, the economic impact of the pandemic has led to financial constraints for individuals, affecting their ability to seek timely BPH treatment. However, with the gradual resumption of healthcare services and the development of vaccination programs, the market recovered in the post-pandemic period, with a renewed emphasis on addressing the unmet needs of BPH patients.

Global Benign Prostatic Hyperplasia (BPH) Treatment Market - By Therapy:

By therapy, the global benign prostatic hyperplasia (BPH) treatment market is bifurcated into Mono Drug Therapy and Combination Drug Therapy segments. The combination drug therapy segment holds a higher market share in the global benign prostatic hyperplasia (BPH) treatment market, due to its enhanced efficacy and comprehensive approach. By combining medications with different mechanisms of action, combination therapy offers improved symptom relief and better outcomes compared to mono drug therapy. The synergistic effects of combined drugs further contribute to its popularity among healthcare providers and patients. Treatment guidelines and recommendations endorsing combination therapy, along with patient preferences for convenience, also drive its market dominance. Streamlining multiple medications into a single combination product enhances medication adherence and patient compliance. These factors collectively contribute to the prominence of combination drug therapy in the BPH treatment market.

Competitive Landscape:

Major players operating in the global benign prostatic hyperplasia (BPH) treatment market include: Astellas Pharma Inc., Eli Lilly and Company, GlaxoSmithKline plc, AstraZeneca plc, Johnson & Johnson, Pfizer Inc., Abbott Laboratories, Boston Scientific Corporation, Medtronic plc, Urologix, LLC, Teleflex Incorporated, Olympus Corporation, Merck & Co., Inc., Allergan plc, and Endo International plc. To further enhance their market share, these companies employ various strategies, including mergers and acquisitions, partnerships, joint ventures, license agreements, and new product launches.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Benign Prostatic Hyperplasia (BPH) Treatment Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Benign Prostatic Hyperplasia (BPH) Treatment Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Table of Contents

1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

2. Executive Summary

3. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Insights

  • 3.1. Industry Value Chain Analysis
  • 3.2. DROC Analysis
    • 3.2.1. Growth Drivers
      • 3.2.1.1. Increasing prevalence of BPH globally.
      • 3.2.1.2. Growing ageing population prone to BPH.
      • 3.2.1.3. Advancements in minimally invasive treatment options.
    • 3.2.2. Restraints
      • 3.2.2.1. High costs associated with BPH treatment procedures
      • 3.2.2.2. Adverse effects and complications associated with certain treatment options
  • 3.3. Opportunities
      • 3.3.1.1. Development of novel and more effective treatment options.
      • 3.3.1.2. Increasing investment in research and development.
    • 3.3.2. Challenges
      • 3.3.2.1. Intense competition among market players.
      • 3.3.2.2. Slow adoption of advanced treatment technologies in certain regions.
  • 3.4. Technology Advancements/Recent Developments
  • 3.5. Regulatory Framework
  • 3.6. Porter's Five Forces Analysis
    • 3.6.1. Bargaining Power of Suppliers
    • 3.6.2. Bargaining Power of Buyers
    • 3.6.3. Threat of New Entrants
    • 3.6.4. Threat of Substitutes
    • 3.6.5. Intensity of Rivalry

4. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Overview

  • 4.1. Market Size & Forecast, 2019-2029
    • 4.1.1. By Value (USD Million)
  • 4.2. Market Share and Forecast
    • 4.2.1. By Therapy
      • 4.2.1.1. Mono drug therapy
      • 4.2.1.2. Combination drug therapy
    • 4.2.2. By Therapeutic Class
      • 4.2.2.1. Alpha blockers
      • 4.2.2.2. 5- alpha-reductase inhibitors
      • 4.2.2.3. Phosphodiesterase-5 inhibitors
      • 4.2.2.4. Others
    • 4.2.3. By Region
      • 4.2.3.1. North America
      • 4.2.3.2. Europe
      • 4.2.3.3. Asia Pacific (APAC)
      • 4.2.3.4. Latin America (LATAM)
      • 4.2.3.5. Middle East and Africa (MEA)

5. North America Benign Prostatic Hyperplasia (BPH) Treatment Market

  • 5.1. Market Size & Forecast, 2019-2029
    • 5.1.1. By Value (USD Million)
  • 5.2. Market Share & Forecast
    • 5.2.1. By Therapy
    • 5.2.2. By Therapeutic Class
    • 5.2.3. By Country
      • 5.2.3.1. United States
      • 5.2.3.1.1. By Therapy
      • 5.2.3.1.2. By Therapeutic Class
      • 5.2.3.2. Canada
      • 5.2.3.2.1. By Therapy
      • 5.2.3.2.2. By Therapeutic Class

6. Europe Benign Prostatic Hyperplasia (BPH) Treatment Market

  • 6.1. Market Size & Forecast, 2019-2029
    • 6.1.1. By Value (USD Million)
  • 6.2. Market Share & Forecast
    • 6.2.1. By Therapy
    • 6.2.2. By Therapeutic Class
    • 6.2.3. By Country
      • 6.2.3.1. Germany
      • 6.2.3.1.1. By Therapy
      • 6.2.3.1.2. By Therapeutic Class
      • 6.2.3.2. United Kingdom
      • 6.2.3.2.1. By Therapy
      • 6.2.3.2.2. By Therapeutic Class
      • 6.2.3.3. Italy
      • 6.2.3.3.1. By Therapy
      • 6.2.3.3.2. By Therapeutic Class
      • 6.2.3.4. France
      • 6.2.3.4.1. By Therapy
      • 6.2.3.4.2. By Therapeutic Class
      • 6.2.3.5. Spain
      • 6.2.3.5.1. By Therapy
      • 6.2.3.5.2. By Therapeutic Class
      • 6.2.3.6. Belgium
      • 6.2.3.6.1. By Therapy
      • 6.2.3.6.2. By Therapeutic Class
      • 6.2.3.7. Russia
      • 6.2.3.7.1. By Therapy
      • 6.2.3.7.2. By Therapeutic Class
      • 6.2.3.8. The Netherlands
      • 6.2.3.8.1. By Therapy
      • 6.2.3.8.2. By Therapeutic Class
      • 6.2.3.9. Rest of Europe
      • 6.2.3.9.1. By Therapy
      • 6.2.3.9.2. By Therapeutic Class

7. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Treatment Market

  • 7.1. Market Size & Forecast, 2019-2029
    • 7.1.1. By Value (USD Million)
  • 7.2. Market Share & Forecast
    • 7.2.1. By Therapy
    • 7.2.2. By Therapeutic Class
    • 7.2.3. By Country
      • 7.2.3.1. China
      • 7.2.3.1.1. By Therapy
      • 7.2.3.1.2. By Therapeutic Class
      • 7.2.3.2. India
      • 7.2.3.2.1. By Therapy
      • 7.2.3.2.2. By Therapeutic Class
      • 7.2.3.3. Japan
      • 7.2.3.3.1. By Therapy
      • 7.2.3.3.2. By Therapeutic Class
      • 7.2.3.4. South Korea
      • 7.2.3.4.1. By Therapy
      • 7.2.3.4.2. By Therapeutic Class
      • 7.2.3.5. Australia & New Zealand
      • 7.2.3.5.1. By Therapy
      • 7.2.3.5.2. By Therapeutic Class
      • 7.2.3.6. Indonesia
      • 7.2.3.6.1. By Therapy
      • 7.2.3.6.2. By Therapeutic Class
      • 7.2.3.7. Malaysia
      • 7.2.3.7.1. By Therapy
      • 7.2.3.7.2. By Therapeutic Class
      • 7.2.3.8. Singapore
      • 7.2.3.8.1. By Therapy
      • 7.2.3.8.2. By Therapeutic Class
      • 7.2.3.9. Vietnam
      • 7.2.3.9.1. By Therapy
      • 7.2.3.9.2. By Therapeutic Class
      • 7.2.3.10. Rest of APAC
      • 7.2.3.10.1. By Therapy
      • 7.2.3.10.2. By Therapeutic Class

8. Latin America Benign Prostatic Hyperplasia (BPH) Treatment Market

  • 8.1. Market Size & Forecast, 2019-2029
    • 8.1.1. By Value (USD Million)
  • 8.2. Market Share & Forecast
    • 8.2.1. By Therapy
    • 8.2.2. By Therapeutic Class
    • 8.2.3. By Country
      • 8.2.3.1. Brazil
      • 8.2.3.1.1. By Therapy
      • 8.2.3.1.2. By Therapeutic Class
      • 8.2.3.2. Mexico
      • 8.2.3.2.1. By Therapy
      • 8.2.3.2.2. By Therapeutic Class
      • 8.2.3.3. Argentina
      • 8.2.3.3.1. By Therapy
      • 8.2.3.3.2. By Therapeutic Class
      • 8.2.3.4. Peru
      • 8.2.3.4.1. By Therapy
      • 8.2.3.4.2. By Therapeutic Class
      • 8.2.3.5. Rest of LATAM
      • 8.2.3.5.1. By Therapy
      • 8.2.3.5.2. By Therapeutic Class

9. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Treatment Market

  • 9.1. Market Size & Forecast, 2019-2029
    • 9.1.1. By Value (USD Million)
  • 9.2. Market Share & Forecast
    • 9.2.1. By Therapy
    • 9.2.2. By Therapeutic Class
    • 9.2.3. By Country
      • 9.2.3.1. Saudi Arabia
      • 9.2.3.1.1. By Therapy
      • 9.2.3.1.2. By Therapeutic Class
      • 9.2.3.2. UAE
      • 9.2.3.2.1. By Therapy
      • 9.2.3.2.2. By Therapeutic Class
      • 9.2.3.3. Qatar
      • 9.2.3.3.1. By Therapy
      • 9.2.3.3.2. By Therapeutic Class
      • 9.2.3.4. Kuwait
      • 9.2.3.4.1. By Therapy
      • 9.2.3.4.2. By Therapeutic Class
      • 9.2.3.5. South Africa
      • 9.2.3.5.1. By Therapy
      • 9.2.3.5.2. By Therapeutic Class
      • 9.2.3.6. Nigeria
      • 9.2.3.6.1. By Therapy
      • 9.2.3.6.2. By Therapeutic Class
      • 9.2.3.7. Algeria
      • 9.2.3.7.1. By Therapy
      • 9.2.3.7.2. By Therapeutic Class
      • 9.2.3.8. Rest of MEA
      • 9.2.3.8.1. By Therapy
      • 9.2.3.8.2. By Therapeutic Class

10. Competitive Landscape

  • 10.1. List of Key Players and Their Offerings
  • 10.2. Global Benign Prostatic Hyperplasia (BPH) Treatment Market Share Analysis, 2022
  • 10.3. Competitive Benchmarking, By Operating Parameters
  • 10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of Covid-19 on Global Benign Prostatic Hyperplasia (BPH) Treatment Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

  • 12.1. Astellas Pharma Inc.
  • 12.2. Eli Lilly and Company
  • 12.3. GlaxoSmithKline plc
  • 12.4. AstraZeneca plc
  • 12.5. Johnson & Johnson
  • 12.6. Pfizer Inc.
  • 12.7. Abbott Laboratories
  • 12.8. Boston Scientific Corporation
  • 12.9. Medtronic plc
  • 12.10. Urologix, LLC
  • 12.11. Teleflex Incorporated
  • 12.12. Olympus Corporation
  • 12.13. Merck & Co., Inc.
  • 12.14. Allergan plc
  • 12.15. Endo International plc
  • 12.16. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

  • 14.1. Qualitative Research
    • 14.1.1. Primary & Secondary Research
  • 14.2. Quantitative Research
  • 14.3. Market Breakdown & Data Triangulation
    • 14.3.1. Secondary Research
    • 14.3.2. Primary Research
  • 14.4. Breakdown of Primary Research Respondents, By Region
  • 14.5. Assumptions & Limitations